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Abstract
Background:  Dyspnea is a common chief complaint in the emergency department (ED);
differentiating heart failure (HF) from other causes can be challenging. Brain Natriuretic Peptide
(BNP) is a new diagnostic test for HF for use in dyspneic patients in the ED. The purpose of this
study is to systematically review the accuracy of BNP in the emergency diagnosis of HF.
Methods: We searched MEDLINE (1975–2005) supplemented by reference tracking. We included
studies that reported the sensitivity and specificity of BNP for diagnosing HF in ED patients with
acute dyspnea. Two reviewers independently assessed study quality. We pooled sensitivities and
specificities within five ranges of BNP cutoffs.
Results: Ten studies including 3,344 participants met inclusion criteria. Quality was variable;
possible verification or selection bias was common. No studies eliminated patients with obvious
medical causes of dyspnea. Most studies used the Triage BNP assay; all utilized a clinical reference
standard. Pooled sensitivity and specificity at a BNP cutoff of 100–105 pg/ml were 90% and 74%
with negative likelihood ratio (LR) of 0.14; pooled sensitivity was 81% with specificity of 90% at
cutoffs between 300 and 400 pg/ml with positive LR of 7.6.
Conclusion: Our analysis suggests that BNP has moderate accuracy in detecting HF in the ED.
Our results suggest utilizing a BNP of less than 100 pg/ml to rule out HF and a BNP of greater than
400 pg/ml to diagnose HF. Many studies were of marginal quality, and all included patients with
varying degrees of diagnostic uncertainty. Further studies focusing on patients with diagnostic
uncertainty will clarify the real-world utility of BNP in the emergency management of dyspnea.
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Background
Heart failure (HF) is a major public health problem in the
United States whose incidence has been rising in recent
years [1,2]. Twelve to 15 million office visits and 6.5 mil-
lion hospital days are attributable to HF each year, and HF
is responsible for more Medicare expenditure than any
other diagnosis[3].
While common, HF can be difficult and time consuming
to diagnose, with no available single definitive test. Brain
Natriuretic Peptide (BNP) is released by the ventricle in
response to increased volume or pressure, and has been
noted to be elevated in patients with HF, offering promise
as a quantitative diagnostic test for the disease. Beginning
in the mid-1990s, BNP has been evaluated as a diagnostic
test for HF in various settings, including primary care and
urgent care. In more recent years its use has become wide-
spread in emergency departments in the evaluation of
acute dyspnea. While the FDA and other organizations in
North America and Europe have recommended its inclu-
sion in the workup of HF, others have commented that
the utility of BNP is not yet clear from the available litera-
ture[4,5].
We conducted a systematic review of the literature to sum-
marize the available evidence about the sensitivity and
specificity of brain natriuretic peptide in the diagnosis of
heart failure in the emergency department.
Methods
We used systematic methods to identify relevant studies,
determine study eligibility, evaluate study methodologi-
cal quality, and summarize findings regarding diagnostic
accuracy [6-9].
Data sources and study eligibility
We conducted a literature search of MEDLINE (1975–
2005) using combinations of the key words diagnosis,
heart failure, congestive heart failure, BNP, natriuretic
peptide or peptides, and dyspnea. The search was con-
structed to retrieve articles which included the key words
"CHF", "heart failure" or "congestive heart failure", along
with "BNP", "natriuretic peptide" or "natriuretic pep-
tides", and either "dyspnea" or "diagnosis" and was lim-
ited to human subjects. We augmented our computerized
literature search by manually reviewing the reference lists
of identified studies and of other published reviews
[5,10,11]. We included articles published in any language.
Two investigators independently evaluated potential arti-
cles to decide if they were eligible for inclusion in the sys-
tematic review. Disagreements were resolved by
discussion. Studies were considered eligible for inclusion
if they 1) addressed the usefulness of BNP to quantify the
probability of HF among patients presenting with acute
dyspnea to an emergency department setting 2) included
at least 50 patients and if 3) the absolute numbers of true-
positive, false-negative, true-negative, and false-positive
observations were available or derivable for the data pre-
sented. Articles assessing the accuracy of N-terminal pro-
brain natriuretic peptide (NT-proBNP) were excluded, as
NT-proBNP represents a distinct diagnostic test with its
own performance characteristics. We attempted to contact
authors of potential articles to provide any missing infor-
mation. In cases of articles with overlapping study sub-
jects, we chose either the article with more complete
information or the article with the larger number of
included participants.
HF is a clinical syndrome which can be challenging to
diagnose, and there is no single test which serves as the cri-
terion standard for its diagnosis [10,12]. We therefore
included studies with a clinical criterion standard, in
which the diagnosis of HF was determined by one or more
expert cardiologists with access to all clinical information,
including assessment of ventricular function and sympto-
matic response to treatment.
Assessment of study quality
The methodological quality of the selected studies was
assessed, and data were abstracted independently by 2
reviewers (DK and TM). We assessed study quality using
the QUADAS[13]method. We utilized an adapted check-
list which excluded items for which articles had been pre-
selected or which were not applicable. Discrepancies were
resolved by consensus.
Variables extracted included the study design, the number
of patients with and without HF, characteristics of the
study population (age distribution, gender, and ethnic-
ity), clinical variables evaluated and whether they were
clearly defined, reference standard utilized, and the diag-
nostic performance of BNP.
The optimal design for assessing the accuracy of a diag-
nostic test is considered to be a prospective blind compar-
ison of the test and the reference standard in a consecutive
series of patients from a relevant clinical popula-
tion[6,14]. To assess the quality of the studies included in
the meta-analysis data were collected regarding the study
design, reference standard, adequacy of patient spectrum,
description of the reasons for patient withdrawals, and the
presence of verification or selection bias. An adequate
description of the spectrum of patients included in a study
can help clinicians know whether to generalize the results
to their patients. We considered that a study met this cri-
terion if the following information was provided about
the study population: 1) demographics including age,
gender and racial distribution, 2) proportion of patientsBMC Emergency Medicine 2007, 7:6 http://www.biomedcentral.com/1471-227X/7/6
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with history of HF and either asthma or COPD, and 3) the
number of patients hospitalized.
Verification bias occurs if the decision to perform the ref-
erence test is based on the result of the test under study.
For instance, if patients with positive, as opposed to neg-
ative, BNP preferentially receive the criterion standard
evaluation, the sensitivity of the test can be falsely ele-
vated because of the incorrect exclusion of false negatives
from the analysis. In cases in which not all patients were
subjected to the reference test, the study was scored as hav-
ing verification bias[15].
Selection bias can be present when not all patients pre-
senting with the relevant condition are included in order
of entry (consecutive) into the study, or when this selec-
tion is not random. If it was not clear from the text that a
consecutive series of patients was included or a random
subset, the corresponding study was scored as non-con-
secutive.
Statistical analysis
To evaluate agreement between raters for the assessments
of study quality, we calculated the observed percentage
agreement and the κ coefficient for interrater reliabil-
ity[16].
The results of diagnostic tests with numerical results can
be conceived not as dichotomously "positive" or "nega-
tive," but in a continuous fashion, in which different
results may impact pre-test probability to different
degrees. Under these circumstances interval likelihood
ratios (LR) can be calculated for ranges of values; for
example, there might be a LR associated with a BNP
between 100 and 200 pg/ml which reflects the impact on
pre-test probability of a BNP greater than 100 but less
than 200. The raw data required to calculate interval LRs
was not available to us for all studies. Data was only avail-
able to calculate pooled LRs. Data at different dichoto-
mous BNP cutoffs; i.e. for a BNP greater than or less than
a particular value. We grouped these cutoffs into ranges
and pooled data from any study that reported sufficient
data to construct a 2 by 2 table for a cutoff value within
that range.
For each study, we recorded the true-positive rate (sensi-
tivity) and the true negative rate (specificity) for various
cutoff values of BNP as provided by each study. The heter-
ogeneity of all indexes was evaluated using a homogeneity
test based on the χ2 test. A result of p < 0.1 was considered
significant given the relatively low power of this test. In
addition, the I2 statistic was calculated to assess the impact
of heterogeneity on the results. This statistic describes the
percentage of the variability in effect estimates that it is
due to heterogeneity rather than sampling error (chance).
A I2 value of 0% represents no heterogeneity and 25, 50,
and 75% indicate low, moderate, and high heterogene-
ity[17]. We planned to pool data regardless of heterogene-
ity so that clinicians could have an overall estimate of the
performance of this diagnostic test, although heterogene-
ity may limit the validity of the pooled estimate.
We pooled data from different studies by grouping their
results within five ranges of BNP cutoffs in pg/ml: 50–80,
100–105, 150–199, 200–299 and 300–400. For each
range of BNP cutoff, we included data from any study that
reported sensitivity and specificity for BNP values in that
range. When studies reported results for more than one
cutoff in the range, we used the cutoff which was closest
to the middle of the range. We utilized the Random Effects
Model to calculate pooled LRs for each BNP cutoff[18].
These LRs can be used to interpret values greater than or
less than a BNP in each cutoff range; they can not be uti-
lized to precisely interpret a BNP value within each cutoff
range.
To assess publication bias, we created a funnel plot of
individual study log odds ratios plotted against a function
of the sample size as described by Deeks et al [19]. We
tested for funnel plot asymmetry based on a regression of
standardized effect estimates against precision to evaluate
whether the intercept deviates from zero[20].
Statistical analyses were performed using SAS version 9.0
(SAS Institute, Cary, NC).
Results
Selection of studies
Figure 1 outlines the flow of article retrieval for the review.
Of the ten included articles, nine were published in Eng-
lish and one was published in French[21]. Data from the
French article was extracted by one of the investigators
(DK) who speaks French, and was excluded from the
kappa calculation. Several studies reported results for
overlapping patient populations [21-32]. Eight studies
reported results from the BNP Multinational
Study[23,24,28-31,33,34]. To avoid duplication, we
retained the report in the New England Journal of Medi-
cine [29] as it included the most complete description of
demographics and BNP performance characteristics. The
patients reported on in the study by Dao[25] et al were a
subset of the patients in the study by Morrison et al[5,32],
so we retained only the Morrison report. The two publica-
tions by Ray[35,36] reported on the same set of patients,
so we retained the larger report. Of the ten studies in the
analysis, none eliminated patients with obvious HF or
lung disease. Many studies included incomplete reports of
demographic and other information. The characteristics
of the studies analyzed are outlined in Table
1[21,26,29,32,36-42].BMC Emergency Medicine 2007, 7:6 http://www.biomedcentral.com/1471-227X/7/6
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The ten studies in the systematic review included 3,344
participants in North America, South America, New Zea-
land and Europe. The mean age of participants ranged
from 64 to 80 years and between 45% and 93% of the par-
ticipants were men. Nine of the ten studies utilized the
Triage BNP Assay[26,29,32,36-40], which is widely used
and commercially available. The other used the AxSYM
BNP assay[41](table 1). In seven studies the expert opin-
ion of two or more cardiologists with access all available
clinical data served as the reference standard for the diag-
nosis of HF; three studies[21,40,41] utilized the opinion
of only one cardiologist.
The spectrum of patients appears to be quite broad in
most studies. Most included primarily older patients; gen-
der distribution varied widely. Between 43 and 100% of
enrolled patients were admitted to the hospital. Since hos-
pital admission criteria are often subjective and may vary
across health care systems, these rates may be due to prac-
tice variation or to variability in disease severity across the
studies. Patients with obvious trauma as a cause of dysp-
nea were excluded from all studies, while all studies
included patients with an obvious medical cause (i.e.
asthma exacerbation, COPD or HF) of their symptoms.
Thus, the patients included in our analysis represent a
population of patients presenting to the emergency
department with dyspnea, with varying degrees of diag-
nostic uncertainty.
Methodological quality and study characteristics
The observed inter-rater agreement for assessment of
study quality was κ = .88[30]. The results of the quality
Flow of studies in the review Figure 1
Flow of studies in the review.
Potentially relevant 
studies identified 
(n=1931) 
Studies retrieved for 
more detailed 
evaluation  
(n=102) 
Additional studies 
from reference lists
(n=2) 
Excluded studies 
(n=1031) 
Not studies of 
diagnostic accuracy
Potentially appropriate 
studies 
(n=29) 
Excluded studies 
(n=76) 
Included studies 
n=10 
Excluded articles (n=19) 
x Duplicated data (n=9) 
x Inappropriate 
population (n=6) 
x Incomplete data for 
calculation of 
sensitivity and 
specificity (n=4) 
Table 1: Characteristics of the studies included in the review
Study 
Year
# 
subjects
Age 
(mean 
+/- SD)
% 
male
History 
of HF 
(%)
History 
of asthma 
or COPD 
(%)
Patients 
admitted 
(%)
BNP 
assay 
used
Final diag-
nosis HF (%)
Cutoff 
(pg/ml)
Sensi-
tivity 
(%)
Speci-
ficity (%)
Jourdain 
2002
125 72† * * * 100 Triage 72 300 94 86
Logeart 
2002
163 67 ± 15 67 49 * 90 Triage 71 100 96 31
Maisel 2002 1,586 64 ± 17 56 33 41 72 Triage 47 100 90 76
Morrison 
2002
321 * 95 42 40 43 Triage 42 105 86 94
Villacorta 
2002
70 72 ± 16 47 37 44 * Triage 51 200 100 97
Lainchbury 
2003
205 70 ± 14 49 25 42 * Triage 34 100 77 84
Knudsen 
2004
155 76† 45 * 47 * Triage 48 100 90 55
Ray 2004 308 80 ± 8 50 20 25 100 Triage 46 100 90 59
Mueller 
2005
251 73† 93 65 * * AxSYM 
BNP
55 100 96 61
Alibay 2005 160 80 ± 14 48 38 34 58 Triage 38 150 94 61
Sensitivity and Specificity are presented for the BNP value closest to 100 pg/ml from each study.
* Not reported † Standard deviation not reportedBMC Emergency Medicine 2007, 7:6 http://www.biomedcentral.com/1471-227X/7/6
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assessment of the included studies are listed in table 2.
Only one of the studies (10%) clearly defined its spectrum
of patients[29]. In all ten studies the diagnosis of HF was
determined without knowledge of the BNP (blinding).
Selection bias was clearly absent in six studies (60%). The
presence of verification bias was difficult to ascertain in
most of the studies, but was possible in three (30%). One
study (10%) had unexplained patient withdrawals[21].
No study reported inter-reader reliability for the reference
standard (kappa), and no evaluated study met all quality
criteria.
A funnel plot did not suggest evidence of publication bias.
Diagnostic accuracy
The sensitivity and specificity of BNP for diagnosing HF
varied (Table 1), and statistically significant heterogeneity
was present (p < .05, I2 > 0.5). Many studies reported sen-
sitivity and specificity of BNP using the cutoff value with
the greatest combined sensitivity and specificity, while
many reported sensitivity and specificity using a cutoff at
or near 100 pg/ml, which has become the conventional
threshold for a positive test. Sensitivity at or near a BNP
cutoff of 100 pg/ml ranged from 86% to 96%. Specificity
at this cutoff ranged from 31% to 94%. Pooled negative
LR for this range was .14 by the random effects model
(Table 3). Sensitivity was not appreciably higher at lower
cutoffs in most studies[26,29,38,39]. Several studies eval-
uated performance characteristics at higher BNP cutoffs,
up to 400. At BNP cutoffs of 150–199 pg/
ml[26,29,32,36,37,39,41], sensitivity was between 85–
94% and specificity ranged widely from 45–85%. BNP
cutoff values between 200 and 299 pg/ml had sensitivities
between 78 and 100% and specificities between 66 and
97%[26,32,36,39,41]. Only 3 studies[21,36,39] evalu-
ated cutoffs above 299; cutoffs of 300–400 pg/ml had sen-
sitivity of 67–94% and specificity between 84 and 92%,
with a pooled positive LR of 7.6 (Table 3). Pooled LRs for
each range of cutoff values are shown in table 3.
Discussion
The current study presents a systematic review of the liter-
ature on the accuracy of B-type natriuretic peptide for
diagnosing HF in the emergency department. Our review
differs from others which have addressed this issue. The
review by Schwam[5] described the individual studies in
detail but did not systematically assess their quality. A
recent review by Wang et al[10] performed quality assess-
ments but did not report all aspects of study quality. A
review by Doust et al[11] performed quality assessments
and pooled data across studies, but calculated a pooled
diagnostic odds ratio, which is not directly applicable to
clinical practice. As the use of BNP has become increas-
ingly common, we feel there is a need for quality assessed
pooled data for clinical application. Our review is the first
to present a complete quality assessment of the included
articles and to pool data in a way that is relevant to prac-
ticing clinicians.
A BNP of 100 pg/ml is often cited as the best cutoff for the
diagnosis of HF[43]. We found a pooled positive LR of 3.4
and negative LR of .14. At higher cutoffs of between 300
and 400 pg/ml, the positive LR rises to 7.6, with a negative
LR of .17. Thus, our analysis suggests that among adult
patients who with suspected heart failure, a low BNP
seems to make HF unlikely, and very high BNP makes HF
likely. BNP values between 100 and 300 pg/ml may not
be helpful in diagnosing HF.
Table 4 demonstrates the utility of BNP in diagnosing HF
in the context of varying pre-test probabilities. With a pre-
test probability of 10% or 30%, a BNP of < 105 pg/ml
Table 2: Quality measures of included studies
Study, Year Were 
important 
inclusions and 
exclusions 
explained?
Was patient 
spectrum 
clearly 
defined?*
Was the diagnosis 
of HF determined 
without 
knowledge of the 
BNP result?
Was 
agreement 
reported for 
the reference 
standard?
Was selection 
bias present?
Was 
verification 
bias 
present?
Were 
withdrawals 
explained?
Jourdain 2002 Yes No Yes No No No No
Logeart 2002 Yes No Yes No No No Yes
Maisel 2002 Yes Yes Yes No Possible No N/A†
Morrison 2002 Yes No Yes No Yes No N/A†
Villacorta 2002 Yes No Yes No No No N/A†
Lainchbury 
2003
No No Yes No Possible Possible N/A†
Knudsen 2004 Yes No Yes No No Possible N/A†
Ray 2004 Yes No Yes No Possible No Yes
Alibay 2005 Yes No Yes No No No N/A†
Mueller 2005 Yes No Yes No No No Yes
*Information available on age, gender, race, prevalence of a HF history and history of asthma and/or COPD, and the percentage of patients admitted 
to the hospital.BMC Emergency Medicine 2007, 7:6 http://www.biomedcentral.com/1471-227X/7/6
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results in a probability of HF of 2% or 5% respectively and
is clinically useful in ruling out HF. A higher pre-test prob-
ability of 70% coupled with the same low BNP results in
a 25% chance of HF, which is less definitive and may
result in further diagnostic testing. A very high pre-test
probability of 90% and a low BNP results in a 56% likeli-
hood of HF. Similarly, a diagnosis of HF can be made in a
patient with a high (70% or 90%) pre-test probability and
an elevated BNP of > 300 pg/ml; while an elevated BNP in
a patient with a low (30%) pre-test probability leads to a
77% chance of HF and might result in further diagnostic
testing.
Several limitations of the evaluated studies should be con-
sidered. First, there were potential methodological issues
including possible selection bias in many of the studies
and verification bias in a few. No studies reported inter-
relater agreement for the reference standard, and a few
studies failed to clarify important inclusion and exclusion
criteria. Most important, however, may be the issue of
spectrum. In studies of diagnostic tests, it is important that
investigators enroll patients in whom there is diagnostic
uncertainty [44], in whom the test would be used in clin-
ical practice. The studies of BNP recruited broadly, and
likely included patients in whom there was diagnostic
uncertainty in addition to patients in whom the diagnosis
was clear. For example, some patients presenting with dys-
pnea certainly had obvious asthma exacerbations, and
these patients were included in the studies of BNP
although they are not patients in whom a BNP assay
would be utilized in clinical practice. The broadness of the
spectrum in this case may have resulted in a biased esti-
mation of the accuracy of the diagnostic test[44,45]. This
potential bias limits the applicability of the included stud-
ies and of our analysis to clinical practice. Some investiga-
tors explored the impact of this broad spectrum by
performing sub-group analysis looking only at patients in
whom there was diagnostic uncertainty. In the Breathing
Not Properly study, BNP did perform well in the subset of
patients with a history of pulmonary disease[30] with sen-
sitivity and specificity of 93% and 77% at a cutoff of 100
pg/ml, similar to that of the larger population. This find-
ing suggests that accuracy of BNP as determined by the
studies overall may in fact reflect the accuracy of the test
in patients in whom there is a high degree of diagnostic
uncertainty. We look forward to a confirmation of these
findings in other populations.
The best evidence in support of the widespread use of a
new diagnostic test is a randomized trial demonstrating
that its use improves quality of care. [46,47] In the case of
BNP, such a trial has already been published. In the B-type
Natriuretic Peptide for Acute Shortness of Breath Evalua-
tion (BASEL) Study[48] Mueller and colleagues per-
formed a single-blind randomized trial in Switzerland in
which patients presenting the emergency department with
acute dyspnea were assigned to a diagnostic strategy
including a single bedside BNP measurement or a "stand-
ard" diagnostic strategy which excluded BNP. As in the
studies included in our analysis, patients with obvious
trauma were excluded. A total of 452 patients were rand-
omized; 58% were men and the mean age was 71 years.
Clinicians were given guidelines for the interpretation of
BNP values. A BNP level of < 100 pg/ml indicated that HF
was unlikely and other causes of dyspnea should be inves-
tigated while a BNP > 500 pg/ml made HF the most likely
diagnosis. No strong conclusions about HF were recom-
mended for patients with values between 100 and 500 pg/
ml. The study found lower rates of hospital admission
(75% vs. 85%), significant reductions in time to discharge
(8 vs. 11 days) and an $1850 reduction in cost in the
group randomized to BNP testing. In-hospital and 30-day
mortality were not significantly different in the two
groups.
On initial inspection these strongly positive results seem
inconsistent with our findings that BNP is only a moder-
ately accurate diagnostic test. In fact, some have criticized
the BASEL study [49]. Patients enrolled in the study
received somewhat scripted care, which may have
included testing that is not routinely performed [50]. The
specific nature of the care of patients in each group and
the diagnostic tests they received was not described in the
publication [48]. The severity of illness in the study group
is also striking. Although presenting symptoms seemed
moderate, 80% of enrolled patients were hospitalized, of
whom 20% were admitted to the intensive care unit, and
Table 4: Impact of high and low BNP results on pre-test 
probabilities
Pre-test 
probability
Post-test probability 
for BNP < 105 pg/ml
Post-test probability 
for BNP > 300 pg/ml
10% 2% 46%
30% 5% 77%
50% 12% 88%
70% 25% 95%
90% 56% 99%
Table 3: Pooled LRs for BNP in emergency department settings
BNP cutoff 
(pg/ml)
Number of studies/
number of patients with 
information on this cutoff
Positive 
LR
Negative 
LR
50–80 4/2109 2.4 .08
100–105 7/2989 3.4‡ .14‡
150–199 8/2944 3.8 .16
200–299 6/1268 4.6 .16
300–400 3/596 7.6‡ .17‡
‡LR from random effects modelBMC Emergency Medicine 2007, 7:6 http://www.biomedcentral.com/1471-227X/7/6
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the median length of stay in the control group was 11
days. While these characteristics may be related to the
standards of practice in Switzerland or to the particulars of
the study, it is unclear whether the population evaluated
is representative of the broad group of patients presenting
with dyspnea to emergency departments.
It is difficult, however, to disregard the dramatic finding of
the BASEL study, and some of the utility of BNP may have
been related to the way in which it was interpreted in the
study. The study utilized two separate diagnostic cutoffs
for BNP: a level of 100 pg/ml to rule out HF and a level of
500 pg/ml to rule in HF. Our determinations of the per-
formance characteristics of BNP support the use of two
diagnostic cutoffs. The pooled likelihood ratio (LR) was
0.14 for a BNP of < 105 pg/ml (pooled sensitivity 90%
and specificity 74%). A LR of < 0.1 can generally rule out
disease independent of pre-test probability and a LR of >
10 can similarly rule in disease independent of pre-test
probability [44]. LRs of between 0.1 and 0.2 or between 5
and 10 have moderate ability to rule out or rule in disease
[44]. The LR of 0.14 indicates that a BNP of < 105 will
moderately lower the pre-test probability of HF, and may
be clinically useful. The performance of a BNP cutoff of
500 pg/ml has not been studied; the highest cutoff we
found in the literature was 399. In this highest cutoff
range of 300–400 pg/ml, the pooled LR for a positive test,
or elevated BNP, is 7.6, which represents moderate ability
to rule in HF. It is possible that using a higher cutoff of
500 would perform better. Clearly, though, a lower cutoff
to rule out HF and a higher cutoff to rule in HF is sup-
ported by the evidence, and has in fact been adopted in
practice guidelines [51].
Our study has some methodological limitations. We
pooled data from different studies with obvious heteroge-
neity, utilizing the random effects model to determine
pooled LRs. We opted to perform pooling despite the het-
erogeneity because we believe that there is a clinical need
for a compilation of findings regarding BNP, so that clini-
cians may understand its utility in clinical practice. We uti-
lized the random effects model to minimize the bias
associated with heterogeneous results, but the validity of
the pooled estimates may still be limited by the presence
of heterogeneity. In addition, we were limited by the qual-
ity of the available data, which was not ideal.
Conclusion
In summary, our analysis suggests that BNP performs
moderately as a diagnostic test for HF in the emergency
department, with very high and very low values contribut-
ing significantly to making a diagnosis. Most of the stud-
ies recruited a wide spectrum of patients presenting with
dyspnea, including patients with diagnostic uncertainty as
well as patients with more apparent diagnoses in whom a
diagnostic test might not be used in clinical practice. In
order to clarify the true performance of this diagnostic test
among patients in whom it is needed, studies which
include only patients with diagnostic uncertainty should
be performed. Until then, BNP can be best utilized by
interpreting separate cutoffs for ruling in HF and ruling
out HF. The BASEL study provides good evidence of the
utility of BNP in a more severely ill population in Switzer-
land, but its findings may not be generalizable to different
populations.
Abbreviations
BNP Brain natriuretic peptide
COPD Chronic obstructive pulmonary disease
ED Emergency department
HF Heart failure
LR Likelihood ratio
NTproBNP N-terminal probrain natriuretic peptide
pg/ml picograms per milliliter
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